Illinois News Desk

DelveInsight’s “Obstructive Sleep Apnea Pipeline Insight 2026” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Obstructive Sleep Apnea pipeline landscape. It covers the Obstructive Sleep Apnea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obstructive Sleep Apnea pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Obstructive Sleep Apnea Pipeline? @ https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight

Key Takeaways from the Obstructive Sleep Apnea Pipeline Report

• On June 04, 2026- Amgen conducted a Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are living with overweight or obesity.
• On June 04, 2026- Eli Lilly and Company announced a phase 3 studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.
• On June 02, 2026- Novo Nordisk A/S initiated a study is being done to look at the efficacy and safety of NNC0487-0111 in participants with excess body weight and obstructive sleep apnoea not treated with positive airway pressure lose weight and improve sleep apnoea. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.
• DelveInsight’s Obstructive Sleep Apnea Pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Obstructive Sleep Apnea treatment.
• The leading Obstructive Sleep Apnea Companies such as Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, Desitin Arzneimittel GmbH, Shionogi Apnimed Sleep Science and others.
• Promising Obstructive Sleep Apnea Therapies such as Sulthiame, AD128, Mannitol, AD313, AVE0657, Eszopiclone, BAY2586116, Atomoxetine, BAY2253651, AD504, Atomoxetine, R-oxybutynin and others.

Want to know which companies are leading innovation in Obstructive Sleep Apnea? @ Obstructive Sleep Apnea Clinical Trials Assessment

The Obstructive Sleep Apnea Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Obstructive Sleep Apnea Pipeline Report also highlights the unmet needs with respect to the Obstructive Sleep Apnea.

Obstructive Sleep Apnea Overview

Obstructive Sleep Apnea (OSA) is a common sleep-related breathing disorder characterized by repeated partial or complete obstruction of the upper airway during sleep. This obstruction leads to disrupted airflow despite ongoing respiratory effort, causing shallow breathing (hypopnea) or brief pauses in breathing (apnea). As a result, oxygen levels may drop, and the body responds by briefly awakening the individual, often with a gasp, snort, or sudden movement. OSA is frequently associated with loud snoring and fragmented, non-restorative sleep. Common symptoms include excessive daytime sleepiness, morning headaches, dry mouth or sore throat, difficulty concentrating, mood changes, night sweats, restless sleep, and may also be linked to Gastroesophageal Reflux Disease (GERD).

Obstructive Sleep Apnea Emerging Drugs Profile

• AD109: Apnimed

AD109 is an investigational, once-daily oral therapy being developed for the treatment of Obstructive Sleep Apnea (OSA), targeting the neuromuscular mechanisms responsible for upper airway collapse during sleep. It acts on the Hypoglossal Motor Nucleus to enhance upper airway dilator muscle activity, thereby helping maintain airway patency and improving oxygen levels. This first-in-class anti-apneic neuromuscular modulator combines aroxybutynin (an antimuscarinic agent) and atomoxetine (a selective norepinephrine reuptake inhibitor) to achieve synergistic therapeutic effects. Designed as a convenient bedtime pill, AD109 is currently under Phase III clinical evaluation as a non-invasive treatment option for patients with mild to severe OSA.

• HRS9531: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

HRS9531 is an investigational therapeutic agent being explored for the treatment of Obstructive Sleep Apnea (OSA), with a focus on addressing underlying metabolic and physiological contributors to the condition. It is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist designed to promote weight loss and improve metabolic health, which are key factors in OSA severity. By reducing body weight and potentially decreasing upper airway obstruction, HRS9531 may help improve breathing patterns during sleep. Currently, the drug is under Phase III clinical evaluation for the treatment of OSA.

If you’re tracking ongoing Obstructive Sleep Apnea Clinical trials, this press release is a must-read @ Obstructive Sleep Apnea Treatment Drugs

The Obstructive Sleep Apnea Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Obstructive Sleep Apnea with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obstructive Sleep Apnea Treatment.
• Obstructive Sleep Apnea Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Obstructive Sleep Apnea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obstructive Sleep Apnea market.

Obstructive Sleep Apnea Companies

Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, Desitin Arzneimittel GmbH, Shionogi Apnimed Sleep Science and others.

Obstructive Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Obstructive Sleep Apnea Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Obstructive Sleep Apnea Pipeline Report covers it all @ Obstructive Sleep Apnea Market Drivers and Barriers, and Future Perspectives

Scope of the Obstructive Sleep Apnea Pipeline Report

• Coverage- Global
• Obstructive Sleep Apnea Companies- Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, Desitin Arzneimittel GmbH, Shionogi Apnimed Sleep Science and others.
• Obstructive Sleep Apnea Therapies- Sulthiame, AD128, Mannitol, AD313, AVE0657, Eszopiclone, BAY2586116, Atomoxetine, BAY2253651, AD504, Atomoxetine, R-oxybutynin and others.
• Obstructive Sleep Apnea Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Obstructive Sleep Apnea Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Obstructive Sleep Apnea Treatment landscape in this detailed analysis @ Obstructive Sleep Apnea Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Obstructive Sleep Apnea: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Obstructive Sleep Apnea (OSA)– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. AD109: Apnimed
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. MOS118: Mosanna Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Obstructive Sleep Apnea Key Companies
21. Obstructive Sleep Apnea Key Products
22. Obstructive Sleep Apnea- Unmet Needs
23. Obstructive Sleep Apnea- Market Drivers and Barriers
24. Obstructive Sleep Apnea- Future Perspectives and Conclusion
25. Obstructive Sleep Apnea Analyst Views
26. Obstructive Sleep Apnea Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-pipeline-insight